EP Patent

EP3406594A1 — Biocatalytic transamination process

Assigned to Organon Pharma UK Ltd · Expires 2018-11-28 · 7y expired

What this patent protects

A novel process is provided for the efficient preparation of an asymmetric compound of structural formula I : employing dynamic kinetic resolution (DKR). The DKR process involves an enzymatic enantioselective amination reaction catalyzed by transaminases. The process can b…

USPTO Abstract

A novel process is provided for the efficient preparation of an asymmetric compound of structural formula I : employing dynamic kinetic resolution (DKR). The DKR process involves an enzymatic enantioselective amination reaction catalyzed by transaminases. The process can be used to manufacture key intermediates in the preparation of poly (ADP-ribose) polymerase (PARP) inhibitors which may be useful for the treatment of cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP3406594A1
Jurisdiction
EP
Classification
—
Expires
2018-11-28
Drug substance claim
No
Drug product claim
No
Assignee
Organon Pharma UK Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.